Keenova Therapeutics plc·4

Jan 5, 6:03 PM ET

ONeill Hugh Paul 4

4 · Keenova Therapeutics plc · Filed Jan 5, 2026

Insider Transaction Report

Form 4
Period: 2026-01-01
ONeill Hugh Paul
EVP, Chief Operations Officer
Transactions
  • Exercise/Conversion

    Ordinary Shares

    2026-01-01+2,0552,875 total
  • Tax Payment

    Ordinary Shares

    2026-01-011,0731,802 total
  • Exercise/Conversion

    Restricted Stock Units

    2026-01-012,05514,385 total
    Ordinary Shares (2,055 underlying)
Footnotes (4)
  • [F1]Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU.
  • [F2]The number of ordinary shares withheld to satisfy tax withholding obligations arising out the vesting of RSUs is based on a percentage and did not take into account any market value as the Issuer's ordinary shares are not listed or quoted on a recognized trading market.
  • [F3]On February 2, 2024, the Reporting Person was granted 5,129 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Outstanding RSUs were subsequently adjusted as described in footnote 4 below.
  • [F4]Reflects that the Reporting Person received 2,761 additional RSUs resulting from the adjustment of the RSUs held by the Reporting Person immediately prior to the separation of Par Health, Inc. ("Par Health") from the Issuer on November 10, 2025, pursuant to the terms of the Employee Matters Agreement by and between the Issuer and Par Health.

Documents

1 file
  • 4
    tm261751-6_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT